Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Equillium, Inc. (EQ : NSDQ)

• Company Description    Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $0.32 Daily Weekly Monthly 20 Day Moving Average: 1,815,091 shares Shares Outstanding: 35.72 (millions) Market Capitalization: $11.39 (millions) Beta: 1.86 52 Week High: $1.50 52 Week Low: $0.27 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -16.05% -19.07% 12 Week -34.40% -43.08% Year To Date -57.36% -59.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2223 Avenida de la Playa Suite 105 - LA JOLLA,CA 92037 USA ph: 858-240-1200 fax: - ir@equilliumbio.com http://www.equilliumbio.com

• General Corporate Information    Officers Bruce D. Steel - Chief Executive Officer and President Daniel M. Bradbury - Chairman of the Board of Directors Jason A. Keyes - Chief Financial Officer Penny Tom - Senior Vice President Peter Colabuono - Director Peer Information Equillium, Inc. (CORR.) Equillium, Inc. (RSPI) Equillium, Inc. (CGXP) Equillium, Inc. (BGEN) Equillium, Inc. (GTBP) Equillium, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29446K106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 35.72 Most Recent Split Date: (:1) Beta: 1.86 Market Capitalization: $11.39 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.14 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.08 Price/Cash Flow: - Price / Sales: 0.28 EPS Growth vs. Year Ago Period: -200.00% vs. Previous Quarter: -50.00% Sales Growth vs. Year Ago Period: -52.32% vs. Previous Quarter: -63.88% ROE 06/30/25 - - 03/31/25 - -74.34 12/31/24 - -37.61 ROA 06/30/25 - - 03/31/25 - -46.75 12/31/24 - -22.02 Current Ratio 06/30/25 - - 03/31/25 - 2.70 12/31/24 - 3.93 Quick Ratio 06/30/25 - - 03/31/25 - 2.70 12/31/24 - 3.93 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -19.62 Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - -19.62 Pre-Tax Margin 06/30/25 - - 03/31/25 - -44.81 12/31/24 - -18.75 Book Value 06/30/25 - - 03/31/25 - 0.30 12/31/24 - 0.54 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©